Machine learning-derived major adverse event prediction of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry.

Artificial intelligence ELECTRa registry Machine learning Outcomes Risk stratification Transvenous lead extraction

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 10 2021
revised: 03 12 2021
accepted: 10 12 2021
pubmed: 1 5 2022
medline: 3 6 2022
entrez: 30 4 2022
Statut: ppublish

Résumé

Transvenous lead extraction (TLE) remains a high-risk procedure. The purpose of this study was to develop a machine learning (ML)-based risk stratification system to predict the risk of major adverse events (MAEs) after TLE. A MAE was defined as procedure-related major complication and procedure-related death. We designed and evaluated an ML-based risk stratification system trained using the European Lead Extraction ConTRolled (ELECTRa) registry to predict the risk of MAEs in 3555 patients undergoing TLE and tested this on an independent registry of 1171 patients. ML models were developed, including a self-normalizing neural network (SNN), stepwise logistic regression model ("stepwise model"), support vector machines, and random forest model. These were compared with the ELECTRa Registry Outcome Score (EROS) for MAEs. There were 53 MAEs (1.7%) in the training cohort and 24 (2.4%) in the test cohort. Thirty-two clinically important features were used to train the models. ML techniques were similar to EROS by balanced accuracy (stepwise model: 0.74 vs EROS: 0.70) and superior by area under the curve (support vector machines: 0.764 vs EROS: 0.677). The SNN provided a finite risk for MAE and accurately identified MAE in 14 of 169 "high (>80%) risk" patients (8.3%) and no MAEs in all 198 "low (<20%) risk" patients (100%). ML models incrementally improved risk prediction for identifying those at risk of MAEs. The SNN has the additional advantage of providing a personalized finite risk assessment for patients. This may aid patient decision making and allow better preoperative risk assessment and resource allocation.

Sections du résumé

BACKGROUND
Transvenous lead extraction (TLE) remains a high-risk procedure.
OBJECTIVE
The purpose of this study was to develop a machine learning (ML)-based risk stratification system to predict the risk of major adverse events (MAEs) after TLE. A MAE was defined as procedure-related major complication and procedure-related death.
METHODS
We designed and evaluated an ML-based risk stratification system trained using the European Lead Extraction ConTRolled (ELECTRa) registry to predict the risk of MAEs in 3555 patients undergoing TLE and tested this on an independent registry of 1171 patients. ML models were developed, including a self-normalizing neural network (SNN), stepwise logistic regression model ("stepwise model"), support vector machines, and random forest model. These were compared with the ELECTRa Registry Outcome Score (EROS) for MAEs.
RESULTS
There were 53 MAEs (1.7%) in the training cohort and 24 (2.4%) in the test cohort. Thirty-two clinically important features were used to train the models. ML techniques were similar to EROS by balanced accuracy (stepwise model: 0.74 vs EROS: 0.70) and superior by area under the curve (support vector machines: 0.764 vs EROS: 0.677). The SNN provided a finite risk for MAE and accurately identified MAE in 14 of 169 "high (>80%) risk" patients (8.3%) and no MAEs in all 198 "low (<20%) risk" patients (100%).
CONCLUSION
ML models incrementally improved risk prediction for identifying those at risk of MAEs. The SNN has the additional advantage of providing a personalized finite risk assessment for patients. This may aid patient decision making and allow better preoperative risk assessment and resource allocation.

Identifiants

pubmed: 35490083
pii: S1547-5271(22)00011-X
doi: 10.1016/j.hrthm.2021.12.036
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

885-893

Informations de copyright

Copyright © 2022 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Vishal S Mehta (VS)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom; Cardiology Department, Guy's and St Thomas' Hospital, London, United Kingdom. Electronic address: vishal.mehta@kcl.ac.uk.

Hugh O'Brien (H)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom.

Mark K Elliott (MK)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom; Cardiology Department, Guy's and St Thomas' Hospital, London, United Kingdom.

Nadeev Wijesuriya (N)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom; Cardiology Department, Guy's and St Thomas' Hospital, London, United Kingdom.

Angelo Auricchio (A)

Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland.

Salma Ayis (S)

School of Population Health and Environmental Sciences, King's College London, London, United Kingdom.

Carina Blomstrom-Lundqvist (C)

Department of Medical Science and Cardiology, Uppsala University, Uppsala, Sweden.

Maria Grazia Bongiorni (MG)

Cardiology Department, Direttore UO Cardiologia 2 SSN, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Christian Butter (C)

Department of Cardiology, Heart Center Brandenburg in Bernau/Berlin & Brandenburg Medical School, Bernau, Germany.

Jean-Claude Deharo (JC)

Department of Cardiology, CHU La Timone, Cardiologie, Service du prof Deharo, Marseille, France.

Justin Gould (J)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom; Cardiology Department, Guy's and St Thomas' Hospital, London, United Kingdom.

Charles Kennergren (C)

Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Sahlgrenska/SU, Goteborg, Sweden.

Karl-Heinz Kuck (KH)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Andrzej Kutarski (A)

Department of Cardiology, Medical University of Lublin, Lublin, Poland.

Christophe Leclercq (C)

Department Ordensklinikum Linz Elisabethinen, Linz, Austria.

Aldo P Maggioni (AP)

Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy; European Society of Cardiology, EORP, Biot, Sophia Antipolis Cedex, France.

Baldeep S Sidhu (BS)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom; Cardiology Department, Guy's and St Thomas' Hospital, London, United Kingdom.

Tom Wong (T)

Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Steven Niederer (S)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom.

Christopher A Rinaldi (CA)

School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London, United Kingdom; Cardiology Department, Guy's and St Thomas' Hospital, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH